Targeting the SPOP protein pathway in prostate cancer
Upstream and downstream targeting of the SPOP ubiquitin signaling pathway in prostate cancer
['FUNDING_R01'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-11159604
This project explores new treatments aimed at the SPOP protein pathway for people with prostate cancer whose tumors have SPOP-related changes.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11159604 on ClinicalTrials.gov |
What this research studies
Researchers will use human prostate tumor samples and laboratory models to understand how changes in the SPOP ubiquitin signaling pathway and its regulator G3BP1 drive cancer growth. The team will map the molecular steps upstream and downstream of SPOP and test reagents that block or mimic these steps in model systems. The work focuses on the 10–15% of prostate cancers with SPOP alterations and includes experiments designed to identify drug targets. Findings are intended to guide future therapies and clinical trials for patients with SPOP-deregulated tumors.
Who could benefit from this research
Good fit: Adults with prostate cancer whose tumors show SPOP mutations or evidence of SPOP pathway deregulation would be the most relevant candidates.
Not a fit: Patients whose tumors lack SPOP pathway changes or who have other molecular subtypes of prostate cancer are unlikely to benefit directly from these specific findings.
Why it matters
Potential benefit: If successful, this work could lead to new targeted therapies and inform clinical trials for patients with SPOP-altered prostate cancer.
How similar studies have performed: Laboratory studies have linked SPOP mutations to prostate cancer behavior, but targeting the SPOP pathway is a relatively new approach with mostly preclinical support so far.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHOU, PENGBO — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: ZHOU, PENGBO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer, Cancer Biology, Cancers